Aridis Pharmaceuticals ARDS · USD

Its shares trade under the ticker ARDS. It has been listed since 14 August 2018. In the fiscal year to 31 December 2022, it reported revenue of $19.3m and a net loss of $30.7m. At that date it held total assets of $14.7m and shareholders' equity of −$24.2m.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California. The company went IPO on 2018-08-14. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Eric PatzerCo-Founder, Executive Chairman of the Board, since 2003$262,800
• Dr. Vu TruongChief Executive Officer, Co-Founder, Chief Scientific Officer, Director, since 2003$660,150
• Dr. Hasan JafriChief Medical Officer$586,774
• Mr. John HamiltonIndependent Director$40,500
• Dr. Susan Windham- BannisterIndependent Director$37,500
• Mr. Dave GentryInvestor Relations, since 2021

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.